Literature DB >> 17204455

Effects of bile diversion in rats on intestinal sphingomyelinases and ceramidase.

R D Duan1, H J Verkade, Y Cheng, R Havinga, A Nilsson.   

Abstract

Alkaline sphingomyelinase (Alk-SMase) and neutral ceramidase (N-CDase) in the intestinal microvillar membrane are responsible for dietary sphingomyelin digestion. The activities of the enzymes require the presence of bile salt, and the enzymes can be released into the gut lumen in active forms by bile salts and trypsin. It is unclear to what extent that the intestinal presence of bile salts is critical for the intraluminal activity of these enzymes. We compared the activities of Alk-SMase, N-CDase, and other types of SMases in control and permanently bile diverted rats. In the intestinal tract of control rats, the activity of Alk-SMase was profoundly higher than those of acid and neutral SMases. Bile diversion reduced Alk-SMase activity by 85% in the small intestinal content, and by 68% in the faeces, but did not significantly change the activity in the intestinal mucosa. Western blot showed a marked reduction of the enzyme in the intestinal lumen but not mucosa. N-CDase activities both in the intestinal mucosa and content were reduced by bile diversion. Bile diversion also decreased aminopeptidase N activity in the content and increased that in the mucosa, but had no effects on that of alkaline phosphatase. In conclusion, the presence of bile salts is important for maintaining high intraluminal levels of Alk-SMase and N-CDase, two key enzymes for hydrolysis of sphingomyelin in the gut. We speculate that the sphingomyelin hydrolysis in cholestatic conditions is impaired not only by reduced hydrolytic activity but also by deficient dissociation of the enzymes from the membrane.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17204455     DOI: 10.1016/j.bbalip.2006.12.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 2.  Ceramide signaling in the gut.

Authors:  Ying Li; Rebekah J Nicholson; Scott A Summers
Journal:  Mol Cell Endocrinol       Date:  2022-01-05       Impact factor: 4.102

3.  Ezetimibe inhibits expression of acid sphingomyelinase in liver and intestine.

Authors:  Yajun Cheng; Fuli Liu; Jun Wu; Yao Zhang; Ake Nilsson; Rui-Dong Duan
Journal:  Lipids       Date:  2009-09-24       Impact factor: 1.880

Review 4.  Alkaline sphingomyelinase (NPP7) in hepatobiliary diseases: A field that needs to be closely studied.

Authors:  Rui-Dong Duan
Journal:  World J Hepatol       Date:  2018-02-27

Review 5.  Sphingomyelinases and Liver Diseases.

Authors:  Naroa Insausti-Urkia; Estel Solsona-Vilarrasa; Carmen Garcia-Ruiz; Jose C Fernandez-Checa
Journal:  Biomolecules       Date:  2020-10-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.